VIKING THERAPEUTICS INC (1VKTX.MI) Stock Income Statement
Europe - BIT:1VKTX - US92686J1060 - Common Stock
21.43 EUR
-1.61 (-6.99%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 212.84M | 150.92M | 100.83M | 70.36M | 55.68M | |||
| Research and Development | 155.32M | 101.64M | 63.81M | 54.23M | 44.98M | |||
| Selling, General, and Administrative Expenses | 57.52M | 49.28M | 37.02M | 16.12M | 10.70M | |||
| Operating Income | -212.84M | -150.92M | -100.83M | -70.36M | -55.68M | |||
| Interest Income/Expense | 41.29M | 40.96M | 14.93M | 1.49M | 690.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -171.55M | -109.96M | -85.89M | -68.87M | -54.99M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -171.55M | -109.96M | -85.89M | -68.87M | -54.99M | |||
| EBITDA | -212.42M | -150.57M | -100.53M | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.53 | -1.01 | -0.91 | -0.90 | -0.71 | |||
| Non GAAP EPS | -1.53 | -1.00 | -0.92 | -0.91 | -0.72 | |||
| Statistics | ||||||||
All data in USD